By addressing translational challenges and tackling off-target toxicities, the 2nd ADC Toxicity Summit is returning at an imperative time to allow you to prevent, predict and mitigate toxicities ...
To gain a better understanding of the data on ADC combinations in aUC ... a high chance of encountering things like hematological toxicity, neutropenia or anemia may require more frequent blood ...
ADCs are currently at the forefront of cancer treatment, but persistent drug development challenges call for a new approach.
Striving for synergistic combinations can promote the ADC bystander effect, limit overlapping toxicity, and help overcome ADC resistance. The approach requires balance, however. There is the risk ...
Novel and promising designs of ADC - Bispecific ADCs (BsADCs) The main source of ADC toxicity is the non-specific binding of antibodies to antigens. 2 Improving the selectivity and specificity of ...
Background: ImmunoGen’s Patent Application & Dispute - In 2014, ImmunoGen, Inc. (Immunogen) filed U.S. Patent Application ...
Our goal is to enhance drug efficacy while minimizing ADC toxicity, offering transformative treatment alternatives for patients worldwide. Moreover, Akeso has established cutting-edge ADC research ...
Akeso begins patient enrolment in phase I trial of AK138 D1 for the treatment of advanced malignancies in Australia: Hong Kong Saturday, March 1, 2025, 12:00 Hrs [IST] Akeso, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback